Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer ResearchGlobeNewsWire • 19m
Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer SymposiumGlobeNewsWire • Wednesday
Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/12/24
Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product DevelopmentGlobeNewsWire • 11/05/24
Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast CancerGlobeNewsWire • 10/31/24
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast CancerGlobeNewsWire • 10/21/24
Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment ContinuumGlobeNewsWire • 10/01/24
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 09/19/24
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast CancerGlobeNewsWire • 09/10/24
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 09/03/24
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/03/24
Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great ChoiceZacks Investment Research • 08/30/24
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast CancerGlobeNewsWire • 08/21/24
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public RelationsGlobeNewsWire • 08/20/24
Atossa Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/12/24
Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast CancerGlobeNewsWire • 07/22/24
Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerGlobeNewsWire • 06/28/24